Further, Oncopeptides AB (publ) is notified that stabilisation measures have been effected in the Company’s shares on Nasdaq Stockholm. The stabilisation period has now ended and no further stabilisation transactions will be effected.
As previously announced, ABG Sundal Collier AB (”ABGSC”) has acted as stabilisation manager in connection with the offer to acquire shares in the Oncopeptides AB (publ) (“Oncopeptides” or the ”Company”) and the listing on Nasdaq Stockholm (the ”Offering”), and ABGSC has, in its capacity as stabilisation manager, been able to effect transactions aimed at supporting the market price of the shares at levels above those which might otherwise prevail in the open market. It has been possible to effect such stabilisation transactions on Nasdaq Stockholm, the OTC market, or otherwise, at any time during the period that started on the date of commencement of trading in the shares on Nasdaq Stockholm (22 February 2017) and ended 30 calendar days thereafter (on 24 March 2017) (the “Stabilisation Period”). ABGSC has, however, not had any obligation to undertake any stabilisation, and it has been possible to discontinue all stabilisation at any time without prior notice. No transactions have been effected to support the market price of the shares at levels above the price in the Offering.
In order to cover potential over-allotment in relation to the Offering, the Company has, at the request of ABGSC and Carnegie Investment Bank AB (the “Joint Global Coordinators”), committed to issue up to 2,119,565 additional new shares, corresponding to a maximum of 15 percent of the number of shares in the Offering at a price corresponding to the price in the Offering. Joint Global Coordinators now notifies that the over-allotment option regarding 977,906 new shares has been exercised.
The Company will thereby be provided with additional funds of approximately SEK 45 million, which means that the Company will have been provided with a total of approximately SEK 695 million through the Offering, before deduction of issue expenses. After registration of the new shares that will be issued within the scope of the over-allotment option, the number of shares and votes in the Company will amount to 39,806,021. The subscription price for the new shares is set to SEK 46 per share, the same as the subscription price as in the Offering.
Further, ABGSC has announced that ABGSC (contact: Carl Rosenius, tel: +46 8 566 286 85), has performed stabilisation (in accordance with Article 3.2(d) of the EU Market Abuse Regulation) on Nasdaq Stockholm in accordance with what is set out below.
|Issuer:||Oncopeptides AB (publ)|
|Offering price:||46 SEK|
|Stabilisation manager:||ABG Sundal Collier AB|
|Date||Quantity||Price (highest)||Price (lowest)||Price (weighted average)||Currency||Market place|
The stabilisation period regarding the Offering has now ended and no further stabilisation transactions will be effected. Specified below is a summary of the stabilisation transactions which have been effected during the stabilisation period in accordance with this press release and the press releases as of 2 March, 13 March and 22 March 2017. All transactions during the stabilisation period have been effected on Nasdaq Stockholm in the price interval of SEK 41.3 and SEK 46 and no stabilisation transactions have been effected on other dates than those specified below.
|Interval per day|
|2017-02-22||42.5 – 45.9|
|2017-02-23||41.8 – 43|
|2017-02-24||41.5 – 44|
|2017-02-27||45 – 45|
|2017-02-28||45.8 – 46|
|2017-03-01||45.6 – 46|
|2017-03-02||45.7 – 46|
|2017-03-03||44.8 – 46|
|2017-03-06||44.3 – 45|
|2017-03-07||43.9 – 44|
|2017-03-08||44 – 44|
|2017-03-09||43 – 43.6|
|2017-03-14||43.8 – 44.3|
|2017-03-15||43.8 – 44|
|2017-03-16||43.8 – 44|
|2017-03-17||43.9 – 44|
|2017-03-20||43.4 – 43.5|
|2017-03-21||42.5 – 43.3|
|2017-03-22||41.3 – 42.4|
|2017-03-23||42.2 – 42.4|
|2017-03-24||41.6 – 42|
Consequently, all shares in Oncopeptides which ABGSC has lent from Stiftelsen Industrifonden and HealthCap VI L.P. in order to cover over-allotment in connection with the Offering will be re-delivered.
For further information, please contact:
Jakob Lindberg, CEO at Oncopeptides
Rein Piir, Head of Investor Relations at Oncopeptides
This information is such that Oncopeptides is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons above, on 24 March 2017 at 7.30 p.m (CET).
Oncopeptides is a research and development stage pharmaceutical company developing drugs for treatment of cancer. Since the founding of the Company in 2000, the Company has focused primarily on the development of the product candidate Ygalo, an innovative peptidase-potentiated alkylator intended for effective and focused treatment of blood-based cancer diseases, and in particular multiple myeloma. Ygalo is intended to demonstrate better results from treatment compared to established alternative drugs in the treatment of patients with multiple myeloma. Ygalo could potentially provide treating physicians with a new treatment option for patients suffering from this severe cancer disease.
This announcement is not being made in and copies of it may not be distributed or sent, directly or indirectly, into the United States, the United Kingdom, Canada, Australia, South Africa, Japan or any other state or jurisdiction in which release, publication or distribution would be unlawful.
This announcement is not an offer of securities for sale in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. Oncopeptides AB does not intend to register any of the securities in the United States or to conduct a public offering of the securities in the United States.
This communication does not constitute an offer of the securities to the public in the United Kingdom. No prospectus has been or will be approved in the United Kingdom in respect of the securities. This communication is being distributed to and is directed only at (i) persons who are outside the United Kingdom or (ii) persons who are investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) and (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “Relevant Persons”). Any investment activity to which this communication relates will only be available to and will only be engaged with, Relevant Persons. Any person who is not a Relevant Person should not act or rely on this document or any of its contents.
Matters discussed in this communication may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as “believe”, “expect”, “anticipate”, “intend”, “may”, “plan”, “estimate”, “will”, “should”, “could”, “aim” or “might”, or, in each case, their negative, or similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialise or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward?looking statements in this presentation are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or any obligation to update or revise the statements in this presentation to reflect subsequent events. Undue reliance should not be placed on the forward-looking statements in this document.
The information, opinions and forward-looking statements contained in this communication speak only as at its date and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm or to release publicly any revisions to any forward?looking statements to reflect events that occur or circumstances that arise in relation to the content of this communication.